Emerald Mutual Fund Advisers Trust’s Soleno Therapeutics SLNO Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,727	Closed	-$6.72M	–	219
2026 Q1	$6.72M	Sell	200,727 -31,758	-14%	-$1.25M	0.33%	99
2025 Q4	$10.8M	Sell	232,485 -147,415	-39%	-$8.08M	0.52%	85
2025 Q3	$25.7M	Sell	379,900 -25,751	-6%	-$1.91M	1.33%	20
2025 Q2	$34M	Buy	405,651 +33,954	+9%	+$2.54M	2.07%	6
2025 Q1	$26.6M	Buy	371,697 +3,123	+0.8%	+$152K	1.88%	7
2024 Q4	$16.6M	Buy	368,574 +135,566	+58%	+$7.02M	1.01%	39
2024 Q3	$11.8M	Sell	233,008 -8,091	-3%	-$387K	0.61%	69
2024 Q2	$9.84M	Buy	241,099 +9,338	+4%	+$396K	0.52%	70
2024 Q1	$9.92M	Buy	231,761 +30,435	+15%	+$1.38M	0.52%	82
2023 Q4	$8.1M	Hold	201,326	–	–	0.43%	92
2023 Q3	$5.94M	Buy	+201,326	New	+$1.22M	0.36%	100

Emerald Mutual Fund Advisers Trust's SLNO Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 200,727 shares — an estimated $6.72M sold.

Emerald Mutual Fund Advisers Trust first reported a position in SLNO in Q3 2023 and held it in 11 quarters. The position peaked at $34M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Emerald Mutual Fund Advisers Trust reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 200,727 Soleno Therapeutics shares in Q2 2026, an estimated $6.72M.
Emerald Mutual Fund Advisers Trust first reported a position in Soleno Therapeutics in Q3 2023 and held it in 11 quarters.
Emerald Mutual Fund Advisers Trust's Soleno Therapeutics position peaked at $34M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.